We begin by discussing each of the three pillars in turn: PILLAR 1: ADDITIVE GENETIC VARIATION IS ABUNDANT For decades, programs of stock improvement have relied on the breeders' equation, based on resemblance between relatives (Lynch and Walsh, 1998). These programs have been tremendously ...
For decades, programs of stock improvement have relied on the breeders’ equation, based on resemblance between relatives (Lynch and Walsh, 1998). These programs have been tremendously successful, resulting in productivity increases of several folds (Falconer and Mackay, 1996). However, the reason ...
Logistic regression as a prediction model explained the significant relationship between the CYP3A4*1B (T/T) genotype as the dependent binary variable and the plasma atorvastatin concentration (in ng/ml) as the predictor variable. The OR was 1.96 (95% CI: 1.50–2.6, P < 0.001) (Table...
Each clone was prepared from a glycerol stock by Clemson University using a standard protocol [15]. This resulted in high-quality end-sequence data. We quantified the BAC DNA using a Nanodrop 1000 (Thermo Scientific) and assessed quality of the 260/280 ratios of each BAC clone. For each ...
Each clone was prepared from a glycerol stock by Clemson University using a standard protocol [15]. This resulted in high-quality end-sequence data. We quantified the BAC DNA using a Nanodrop 1000 (Thermo Scientific) and assessed quality of the 260/280 ratios of each BAC clone. For each ...
performance of the prediction model for discrimination. A P value < 0.05 was considered statistically significant. The pharmacokinetic profile of atorvastatin was calculated via linear regression via the equation y = a + bx, where y is the area under the peak (AUP) ratio of the ...
were employees or contractors of Digbi Health and may hold stocks or stock options on Digbi Health. R.S. was CEO and founder of Digbi Health. P.D. was an advisor to Digbi Health and has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, ...
were employees or contractors of Digbi Health and may hold stocks or stock options on Digbi Health. R.S. was CEO and founder of Digbi Health. P.D. was an advisor to Digbi Health and has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, ...
were employees or contractors of Digbi Health and may hold stocks or stock options on Digbi Health. R.S. was CEO and founder of Digbi Health. P.D. was an advisor to Digbi Health and has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, ...